Earnings ·
Caris Life Sciences reported second quarter 2026 financial results on August 5, 2026
CAICaris Life Sciences, Inc.
Caris Life Sciences reported second quarter 2026 financial results on August 5, 2026. Total revenue increased 45% to $263.7 million, driven by a 55% rise in molecular profiling services revenue to $252.3 million and approximately 59,200 clinical cases. The company achieved a gross margin of 68%, reported a net loss of $0.6 million, and generated positive Adjusted EBITDA of $55.7 million. Management raised full-year 2026 revenue guidance to $1.03–$1.04 billion, reflecting expected growth of 27% to 28%. Additionally, the company announced a share repurchase program with approximately $82.1 million remaining under existing authorization and launched Caris Detect, a multi-cancer early detection blood test. Caris Life Sciences operates in the precision medicine and molecular diagnostics industry, developing genomic testing solutions for oncology.